Conducting real-world research in rheumatology is challenging. Patients often present with multiple comorbidities, disease measures are inconsistently captured in routine care, and traditional data sources don’t always reflect full patient journeys across specialties. In this webinar, OM1 experts will share how AI-enabled, multi-source real-world data can help overcome these barriers and deliver more robust, generalizable insights. Drawing on recent research and case studies, including a large real-world study of rheumatoid arthritis patients, we’ll highlight how novel endpoints such as estimated Clinical Disease Activity Index (CDAI) and advanced analytics are closing evidence gaps and reshaping the future of rheumatology research.
Key Insights:
- Introduction to Scatter-Free Absorption (SFA) technology – a new way to quantify payloads in intact LNPs in 2 minutes analysis time per sample
- Case studies and data demonstrating quantification of payloads, e.g. RNA, in LNP formulations
- Discussion on how SFA compares with methods such as the RiboGreen assay in terms of ease of use and precision of answers
- Introduction to Marama Labs’ CloudSpec instrument and how it translates into faster development times in nanomedicine development
- Q&A session where participants can interact with industry experts, gaining deeper insights into the practical applications and potential of SFA
Key Highlights:
- Learn emerging techniques in using AI to power research through case examples
- Understand how LLM extraction is applied to clinical notes and improves data quality
- Explore endpoint estimation for critical outcomes such as CDAI, BASDAI, Hurley
- Hear how subtyping is revealing new forms of disease and can identify patients more likely to progress from psoriasis to psoriatic arthritis
Why Attend?
This is a fantastic opportunity to learn more about the treatment landscape in this complex area.
Join us for an informative session that will provide fascinating insights into how RWE can overcome these challenging questions in rheumatology.
Webinar Leaders
Chandrasekar “Chandra” Gopalakrishnan
Senior Principal Epidemiologist, OM1
Carl Marci, MD
Chief Clinical Officer, OM1
Key Insights:
- Introduction to Scatter-Free Absorption (SFA) technology – a new way to quantify payloads in intact LNPs in 2 minutes analysis time per sample
- Case studies and data demonstrating quantification of payloads, e.g. RNA, in LNP formulations
- Discussion on how SFA compares with methods such as the RiboGreen assay in terms of ease of use and precision of answers
- Introduction to Marama Labs’ CloudSpec instrument and how it translates into faster development times in nanomedicine development
- Q&A session where participants can interact with industry experts, gaining deeper insights into the practical applications and potential of SFA
About OM1:
OM1 is pioneering cutting-edge healthcare innovation through its insights-driven AI technology and data. OM1 specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.
You May Also Be Interested In…
Learn More About Consulting
- We are specialist life sciences market research and consultants, delivering tailored insights across the full drug development and commercialisation lifecycle.
- Combines scientific expertise, expert networks, and proprietary Beacon data to transform complex data into clear, strategic decisions.
- Provides fully customised research, spanning qualitative interviews, quantitative analysis, and desk research, aligned to your specific business objectives.
- Helps biopharma teams reduce risk, identify opportunities, and accelerate decision-making with actionable, decision-ready insights.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
